O TYM ODCINKU
Rheumatology Network sat down with Andrew L Concoff MD, FACR, CAQSM, to discuss value-based care, including the benefits, collaborate approach to working with payers, the revenue and cost savings, and how value-based care can support routine and consistent health visits.
Time stamps:
0:43: What is value-based care?
1:04: How is value-based care different from fee-for-service models?
4:11: What are the revenue and cost savings of value-based care?
6:39: What are the benefits of value-based care and how does it allow for personalized patient care?
9:10: How does a collaborative approach to working with payers benefit practices and patients?
12:58: How does value-based care support routine and consistent health visits versus urgent appointments?
15:14: Is there anything else you’d like our audience to know before we wrap up?
Time stamps:
0:43: What is value-based care?
1:04: How is value-based care different from fee-for-service models?
4:11: What are the revenue and cost savings of value-based care?
6:39: What are the benefits of value-based care and how does it allow for personalized patient care?
9:10: How does a collaborative approach to working with payers benefit practices and patients?
12:58: How does value-based care support routine and consistent health visits versus urgent appointments?
15:14: Is there anything else you’d like our audience to know before we wrap up?
Język angielski
Stany Zjednoczone
TRANSKRYPCJA 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
WYSZUKAJ MINIONE ODCINKI
Wyszukaj minione odcinki Overdrive by Rheumatology Network.
INNE ODCINKI W TYM PODCASCIE
Roy Fleischmann, MD, discusses the recent Pfizer press release touching upon the safety of JAK inhibitors. He explains the recent scrutiny of JAKs, the concerns some rheumatologists have in regard to JAK inhibitors, and his personal opinions on prescribing JAK inhibiting drugs to his patients.
Tim…
This week, we sat down with Philip J. Mease, MD, to discuss his study, “Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis.”
Time stamps:
0:35: Can you begin by giving me a general overview of the current treatment …
This week, we sat down with Daniel Hernandez, MD, and Shilpa Venkatachalam, PhD, MPH, of CreakyJoints, to highlight health disparities in marginalized communities and introduce their exciting new venture, CreakyJoints Espanol.
Time stamps:
1:17: The COVID-19 pandemic has exposed health dispariti…
E Michael Lewiecki, MD, discusses “Controversies in Osteoporosis” and “What's New in Osteoporosis for 2021?” We deep dive into recent controversies and trends in osteoporosis management, predictions for 2022, and how COVID-19 had impacted the treatment landscape for rheumatologists.
Time stamps:
…
Zastrzeżenie: Podcast i grafika osadzone na tej stronie pochodzą z Rheumatology Network, który jest własnością jego właściciela i nie jest powiązany ani wspierany przez Listen Notes, Inc.
EDYTUJ
Dziękujemy za pomoc w aktualizowaniu podcastowej bazy danych.
